Trial Profile
ACE: Proof of Concept Phase I/II Trial of the CXCR2 Antagonist AZD5069, Administered in Combination With Enzalutamide, in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs AZD 5069 (Primary) ; Enzalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms ACE
- 01 Nov 2023 Results published in the Nature
- 12 Jul 2023 Status changed from active, no longer recruiting to discontinued (Due to discontinuation of production of IMP).
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress